Increased incidence and unusual presentations of CMV disease in kidney transplant recipients after conversion to belatacept

This publication has 29 references indexed in Scilit:

• Improving our mechanistic understanding of the indirect effects of CMV infection in transplant recipients
  American Journal of Transplantation, 2019
• Ten-year outcomes in a randomized phase II study of kidney transplant recipients administered belatacept 4-weekly or 8-weekly
  American Journal of Transplantation, 2017
• Long-Term Outcomes in Belatacept- Versus Cyclosporine-Treated Recipients of Extended Criteria Donor Kidneys: Final Results From BENEFIT-EXT, a Phase III Randomized Study
  American Journal of Transplantation, 2016
• Long-Term Belatacept Exposure Maintains Efficacy and Safety at 5 Years: Results From the Long-Term Extension of the BENEFIT Study
  American Journal of Transplantation, 2013
• CMV: Prevention, Diagnosis and Therapy
  American Journal of Transplantation, 2013
• Prophylaxis, Preemption and Drug Resistance in CMV Infection: Too Little, Too Much or Just Right?
  American Journal of Transplantation, 2011
• A Phase III Study of Belatacept‐based Immunosuppression Regimens versus Cyclosporine in Renal Transplant Recipients (BENEFIT Study)
  American Journal of Transplantation, 2010
• Direct and indirect effects of cytomegalovirus: can we prevent them?
  Enfermedades Infecciosas y Microbiología Clínica, 2010
• Effect of cytomegalovirus prophylaxis with immunoglobulin or with antiviral drugs on post-transplant non-Hodgkin lymphoma: a multicentre retrospective analysis
  The Lancet Oncology, 2007
• Rational Development of LEA29Y (belatacept), a High-Affinity Variant of CTLA4-Ig with Potent Immunosuppressive Properties
  American Journal of Transplantation, 2005